BTIG Research assumed coverage on shares of Bruker (NASDAQ:BRKR) in a report published on Friday. The brokerage issued a buy rating and a $42.00 price objective on the medical research company’s stock.

Several other brokerages also recently commented on BRKR. Evercore ISI started coverage on Bruker in a research note on Wednesday. They issued an in-line rating and a $36.00 price objective for the company. Citigroup increased their price objective on Bruker from $29.00 to $34.00 and gave the stock a neutral rating in a research note on Friday, November 3rd. Zacks Investment Research downgraded Bruker from a buy rating to a hold rating in a research note on Friday, November 10th. Cowen reissued a hold rating and issued a $35.00 price objective on shares of Bruker in a research note on Thursday, December 21st. Finally, Goldman Sachs Group reissued a sell rating and issued a $24.00 price objective on shares of Bruker in a research note on Tuesday, September 26th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the stock. The company currently has an average rating of Hold and an average price target of $32.38.

Bruker (NASDAQ BRKR) opened at $35.99 on Friday. Bruker has a 52 week low of $21.68 and a 52 week high of $36.53. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.60 and a current ratio of 2.60. The firm has a market capitalization of $5,443.14, a P/E ratio of 38.29, a P/E/G ratio of 2.63 and a beta of 1.12.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.02. Bruker had a return on equity of 25.83% and a net margin of 8.85%. The business had revenue of $435.60 million for the quarter, compared to the consensus estimate of $415.45 million. During the same period in the prior year, the business earned $0.32 EPS. The firm’s revenue for the quarter was up 10.6% on a year-over-year basis. analysts anticipate that Bruker will post 1.19 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Friday, December 22nd. Stockholders of record on Monday, December 4th were issued a $0.04 dividend. This represents a $0.16 annualized dividend and a dividend yield of 0.44%. The ex-dividend date of this dividend was Friday, December 1st. Bruker’s dividend payout ratio is presently 17.02%.

Several hedge funds have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio grew its holdings in shares of Bruker by 24.1% in the third quarter. Public Employees Retirement System of Ohio now owns 58,142 shares of the medical research company’s stock valued at $1,730,000 after acquiring an additional 11,274 shares in the last quarter. GSA Capital Partners LLP grew its holdings in shares of Bruker by 158.9% in the third quarter. GSA Capital Partners LLP now owns 109,601 shares of the medical research company’s stock valued at $3,261,000 after acquiring an additional 67,265 shares in the last quarter. Piedmont Investment Advisors LLC grew its holdings in shares of Bruker by 23.8% in the third quarter. Piedmont Investment Advisors LLC now owns 64,664 shares of the medical research company’s stock valued at $1,924,000 after acquiring an additional 12,429 shares in the last quarter. California Public Employees Retirement System grew its holdings in shares of Bruker by 9.7% in the third quarter. California Public Employees Retirement System now owns 248,216 shares of the medical research company’s stock valued at $7,384,000 after acquiring an additional 22,016 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its holdings in shares of Bruker by 8.2% in the third quarter. Point72 Asset Management L.P. now owns 667,400 shares of the medical research company’s stock valued at $19,855,000 after acquiring an additional 50,800 shares in the last quarter. 65.60% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.watchlistnews.com/bruker-brkr-receives-new-coverage-from-analysts-at-btig-research/1797489.html.

Bruker Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with Analyst Ratings Network's FREE daily email newsletter.